Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 20, 2025HaematologicaOpen Access

JAK inhibitor selection in challenging scenarios of myelofibrosis: a review

View Full Paper
Ask AI
Bookmark
Share

Authors

PVPankit VachhaniRMRuben MesaJMJohn Mascarenhas

Discussion

Loading...

Member takes

Overview

This review highlights treatment recommendations for myelofibrosis, suggesting individualized JAK inhibitor selection based on patient characteristics.

Key Points

  • This review aims to summarize JAK inhibitors used for myelofibrosis and their selection based on patient scenarios.
  • Reviewed current data on available JAK inhibitors
  • Discussed four hypothetical patient cases
  • Examined individual patient characteristics for treatment decisions
  • Considered safety profiles and clinical factors for JAK inhibitors
  • Hematopoietic stem cell transplant is the only curative treatment modality for myelofibrosis
  • JAK inhibitors provide symptom relief and reduce spleen size
  • Emerging real-world data on newer JAK inhibitors like ruxolitinib and fedratinib
  • Treatment recommendations are tailored based on specific patient circumstances

Cite This Study

Vachhani et al. (2025) studied this question.

synapsesocial.com/papers/6924f07ac0ce034ddc34fecdhttps://doi.org/10.3324/haematol.2025.288654
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib2024
  2. 2Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors2026
  3. 3Comparative efficacy and safety of JAK inhibitor-based strategies in JAK inhibitor-naïve myelofibrosis: A systematic review and network meta-analysis2026
  4. 4JAK inhibitors vs traditional therapy for myelofibrosis; A meta-analysis of randomized clinical trials.2026
  5. 5Advances in pharmacotherapy for myelofibrosis: what is the current state of play?2024